Designing of multi-epitope chimeric vaccine using immunoinformatic platform by targeting oncogenic strain HPV 16 and 18 against cervical cancer

Kumar, Anoop; Sahu, Utkarsha; Kumari, Pratima; Dixit, Anshuman; Khare, Prashant

doi:10.1038/s41598-022-13442-4

Cited by 17 publications

(14 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Alpha helix and coilcontaining proteins and peptides are significant structural antigens because antibodies can identify them. 24 The amino acid composition has shown that leucine residues are the most frequently occurring amino acids in all three proteins, i.e., E6, E7, and L1 of HPV-45. The most intriguing fact is that leucine residues have been studied earlier due to their significance in histone deacetylases (HDACs) binding.…”

Section: Discussionmentioning

confidence: 99%

In-silico Analysis of Human Papillomavirus – 45 E6, E7 & L1 Proteins as Potential Immunogens

Padavu¹,

Kumar²,

Kumar³

et al. 2023

J. Pure Appl. Microbiol.

Self Cite

View full text Add to dashboard Cite

Globally, cervical cancer is the fourth most common cancer among women. After being cloned from a recurring cervical lesion in 1987, Human papillomavirus (HPV) type-45 was identified as a high-risk HPV type. It is the third most common cancer-causing HPV subtype, after HPV-16 and HPV-18. Immunogenic epitopes and structural features provide the most useful information for vaccine development. Computational algorithms provide quick, simple, trustworthy, and cost-efficient methods for predicting immunogenic epitopes. In this study, both B and T cell epitopes have been identified as potential immunogens that can elicit a response from the host system. Three potential B-cell epitopes, i.e., SIAGQYRGQCNTCCDQ, LQEIVLHLEPQNELDP, and DSTVYLPPPSVARVVS, were identified in this study. A potential epitope for E6 (ATLERTEVY) was predicted to 8 MHC-I alleles (HLA-A*30:02, HLA-B*15:01, HLA-A*01:01, HLA-A*26:01, HLA-A*32:01, HLA-B*35:01, HLA-B*58:01, HLA-A*11:01) and for L1 epitope (NVFPIFLQM) was predicted for 4 MHC-I alleles (HLA-A*30:02, HLA-A*32:01, HLA-B*53:01, HLA-B*51:01). To conclude, the epitopes identified here might potentially be useful for developing a cervical cancer vaccine against HPV-45 strains, but in vitro and in vivo trials are needed to validate their safety and efficacy.

show abstract

Section: Discussionmentioning

confidence: 99%

In-silico Analysis of Human Papillomavirus – 45 E6, E7 & L1 Proteins as Potential Immunogens

Padavu¹,

Kumar²,

Kumar³

et al. 2023

J. Pure Appl. Microbiol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…The PSIPRED results reveal that the vaccine construct possessed 19.7% alpha-helix, 16.9% extended strands and 63.4% coils. It is to be noted that proteins having an alpha-helix and coils are important as structural antigens for they can be recognised by antibodies [54]. The 3D structure of the final vaccine construct was predicted using the ROBETTA sever, and model 2 was chosen based on the model evaluation using the SAVES server.…”

Section: Prediction and Assessment Of Secondary And 3d Structure Of T...mentioning

confidence: 99%

Design of a potential Sema4A-based multi-epitope vaccine to combat triple-negative breast cancer: an immunoinformatic approach

Paranthaman

Shanthi

2023

Med Oncol

View full text Add to dashboard Cite

Immunotherapy is revamping the therapeutic strategies for TNBC owing to its higher mutational burden and tumour-associated antigens. One of the most intriguing developments in cancer immunotherapy is the focus on peptide-based cancer vaccines. Thus, the current work aims to develop an efficient peptide-based vaccine against TNBC that targets Sema4A, which has recently been identified as a major regulator of TNBC progression. Initially, the antigenic peptides derived from Sema4A were determined and evaluated based on their capability to provoke immunological responses. The assessed epitopes were then linked with a suitable adjuvant (RpfB and RpfE) and appropriate linkers (AAY, GPGPG, KK and EAAAK) to preclude junctional immunogenicity. Eventually, docking and dynamics simulations are performed against TLR-2, TLR-4, TLR-7 and TLR-9 to assess the interaction between the vaccine construct and TLR receptors, as the TLR signalling pathway is critical in the host immune response. The developed vaccine was then exposed to in silico cloning and immune simulation analysis. The findings suggest that the designed vaccine could potentially evoke significant humoral and cellular immune responses in the intended organism. Considering these outcomes, the final multi-epitope vaccine could be employed to serve as an effective choice for TNBC management and may open new avenues for further studies.

show abstract

“…Another vaccine for the treatment of cervical cancer was designed with epitopes of HPV16/18 E5 and E7 proteins and showed stability, non-toxicity, and non-allergenicity [ 38 ]. Kumar et al [ 39 ] went further, designing a multi-epitope platform with prophylactic and therapeutic potential against HPV16 and 18 from peptides obtained from L1, E5, E6, and E7 proteins that can induce an immune response against CD8+ and TCD4+ lymphocytes.…”

Section: Strategies To Improve the Efficiency Of Nucleic Acid Vaccinesmentioning

confidence: 99%

Third-Generation Vaccines: Features of Nucleic Acid Vaccines and Strategies to Improve Their Efficiency

Melo

Macêdo

Invenção

et al. 2022

Genes

View full text Add to dashboard Cite

Gene immunization comprises mRNA and DNA vaccines, which stand out due to their simple design, maintenance, and high efficacy. Several studies indicate promising results in preclinical and clinical trials regarding immunization against ebola, human immunodeficiency virus (HIV), influenza, and human papillomavirus (HPV). The efficiency of nucleic acid vaccines has been highlighted in the fight against COVID-19 with unprecedented approval of their use in humans. However, their low intrinsic immunogenicity points to the need to use strategies capable of overcoming this characteristic and increasing the efficiency of vaccine campaigns. These strategies include the improvement of the epitopes’ presentation to the system via MHC, the evaluation of immunodominant epitopes with high coverage against emerging viral subtypes, the use of adjuvants that enhance immunogenicity, and the increase in the efficiency of vaccine transfection. In this review, we provide updates regarding some characteristics, construction, and improvement of such vaccines, especially about the production of synthetic multi-epitope genes, widely employed in the current gene-based vaccines.

show abstract

Designing of multi-epitope chimeric vaccine using immunoinformatic platform by targeting oncogenic strain HPV 16 and 18 against cervical cancer

Cited by 17 publications

References 60 publications

In-silico Analysis of Human Papillomavirus – 45 E6, E7 & L1 Proteins as Potential Immunogens

In-silico Analysis of Human Papillomavirus – 45 E6, E7 & L1 Proteins as Potential Immunogens

Design of a potential Sema4A-based multi-epitope vaccine to combat triple-negative breast cancer: an immunoinformatic approach

Third-Generation Vaccines: Features of Nucleic Acid Vaccines and Strategies to Improve Their Efficiency

Contact Info

Product

Resources

About